Echinocandins (Caspofungin, Micafungin, Anidulafungin)

Caspofungin, micafungin and anidulafungin are three real, FDA-approved cyclic lipopeptide antifungals — grouped on one page because they share a genuinely novel mechanism that targets something human cells don't even have — though a real EU-only warning based on rat liver-tumor data singled out micafungin specifically, and the FDA never followed with an equivalent warning.

A mechanism daptomycin's antibacterial cousins don't share

Caspofungin, micafungin and anidulafungin are cyclic lipopeptide antifungals — structurally in the same broad family as this site's daptomycin, but built to kill fungi rather than bacteria. All three block 1,3-β-D-glucan synthase, the enzyme fungi use to build glucan into their cell walls. That target doesn't exist in human cells at all — mammalian cells have no cell wall — a genuinely different safety proposition from older antifungals like amphotericin B, which works by binding ergosterol, a molecule structurally close enough to human cholesterol to cause real toxicity.

Three approvals, three years apart

Caspofungin (Cancidas, Merck) was first, FDA-approved in 2001 as the first-in-class echinocandin, developed as a semisynthetic derivative of pneumocandin B0, a natural cyclic peptide isolated from the fungus Glarea lozoyensis. Micafungin (Mycamine, Astellas) followed on 16 March 2005, and anidulafungin (Eraxis, Pfizer) on 17 February 2006 — three separate companies, three separate approvals, converging on the same mechanism within five years of each other.

The pivotal trial: as good as amphotericin B, with fewer side effects

Caspofungin's pivotal trial (Mora-Duarte et al., N Engl J Med 2002;347:2020-2029, PMID 12490683) randomized 239 patients with invasive candidiasis to double-blind caspofungin or amphotericin B deoxycholate. In the modified intention-to-treat analysis, caspofungin produced a favorable response in 73.4% of patients versus 61.7% for amphotericin B — and specifically for candidemia, 71.7% versus 62.8% — with significantly fewer drug-related adverse events in the caspofungin group. That trial, more than any single approval date, is why echinocandins largely displaced amphotericin B as first-line therapy for invasive candidiasis in patients able to tolerate either drug.

A real EU-only warning that the FDA never matched

Not every echinocandin got the same regulatory treatment. Long-term rodent toxicity studies found altered hepatocellular foci and liver tumors (adenomas and carcinomas) in rats given high-dose micafungin — a finding specific to micafungin's own animal data, not shared by caspofungin or anidulafungin. The EMA responded with a boxed warning and restricted micafungin's European label to use only when other antifungal agents aren't suitable; the FDA reviewed the same underlying animal data and did not add an equivalent warning to the US label. Long-term human surveillance since approval hasn't shown an increased rate of liver disease or tumors in people, and whether the rat finding has any real human relevance remains genuinely unresolved — but the US and EU reached different labeling conclusions from the same evidence, worth knowing if you encounter micafungin's EU label and wonder why it reads more cautiously than its FDA counterpart.

Current status

All three remain in active use for invasive candidiasis and candidemia, and as prophylaxis in stem-cell transplant and other high-risk patients (caspofungin and micafungin especially); none reliably covers Cryptococcus or most molds, though caspofungin has a salvage-therapy indication against Aspergillus. These are hospital/IV-only drugs with no oral formulation, no wellness application, and no grey-market presence — a purely clinical antifungal class.